Lessons from the ANTES B+ study
enero 14, 2026
Lessons from the ANTES B+ study highlighting challenges in COPD clinical trials, recruitment difficulties, and implications for future study design.
Lessons from the ANTES B+ study highlighting challenges in COPD clinical trials, recruitment difficulties, and implications for future study design.
Review of the treatable traits approach in bronchiectasis, exploring phenotypes, endotypes, comorbidities, and its translation into clinical practice.
Video de la presentación «Novedades GOLD 2026», en el que se trataron, entre otros aspectos: cambios en diagnóstico de la EPOC, tratamiento, comparativa con GESEPOC, etc.
Discover how personalized COPD care integrates phenotypes, endotypes, GETomics, trajectome, syndemics, and treatable traits to improve patient outcomes.
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
Expert consensus on patient-centred strategies to manage multimorbidity in COPD, aiming to improve outcomes and reduce disease burden.
Sputum metagenomics reveals pan-European variation in microbial and resistome profiles in bronchiectasis: an EMBARC-BRIDGE study.